Genedrive Share Discussion Threads

[maverickps123] 05/7/2022 10:51

News incoming!

[snowy20] 05/7/2022 10:48

50K buyers cleaning up more shares .

[tryharderr] 05/7/2022 10:48

If they release RNS this week hello 50p

[zen12] 05/7/2022 10:45

Big buys ...leak?

[snowy20] 05/7/2022 10:41

Will it be AIHL RNS
Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.



or POC RNS
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive® COV19-ID Kit in the United Kingdom. Genedrive's application for approval, under the requirements that came into force on 28 July 2021 via The Medical Devices (Coronavirus Test Device Approvals Regulations (2021)), was made on 21 December 2021.



Since submission for approval, the product has undergone positive external validation, commercial partners have been engaged in specific countries, and product claims have been expanded to include the testing of asymptomatic patients.



Information about the Genedrive® COV19-ID Kit can be found at hxxps://www.genedrive.com/assays/cov19-id-assay.php



David Budd, CEO of genedrive plc, said: "We are very pleased to have received a CTDA, which now allows the UK access to the fastest point-of-care COVID molecular test. The performance of the test has met CTDA standards in all regards, which positions genedrive well to engage in opportunities as they develop going forwards in the UK."



The Genedrive® COV19-ID Kit is a rapid molecular diagnostic test that delivers positive results as quickly as 7.5 minutes and negative results at 17 minutes. It utilises Reverse-Transcription Loop Mediated Isothermal Amplification (RT-LAMP) and a proprietary buffer formulation to achieve rapid results without requirement for user viral extraction steps. Performed directly from a mid-turbinate nasal swab, the assay targets the ORF1ab and N genes of the SARS-CoV-2 genome, adding robustness against emerging SARS-CoV-2 variants.

[snowy20] 05/7/2022 10:34

Lotta buying days before Big rise in March when RNS was released .

[regandharry5] 05/7/2022 10:29

Looks like approval be NICE isoniazid the cards. RNS shortly.

[snowy20] 05/7/2022 10:28

100k BUY .

[snowy20] 05/7/2022 10:11

This buying volume .RNS might be days away .

[mjb252] 05/7/2022 10:07

Where's your sense of humour gone?

[snowy20] 05/7/2022 10:06

35P Soon .When RNS watch for Quid .

[tryharderr] 05/7/2022 09:25

30p coming soon before news

[snowy20] 05/7/2022 08:06

Upwards 19.30 paid .

[snowy20] 04/7/2022 08:28

Upwards 18.90 paid .

[snowy20] 04/7/2022 08:02

Good move up this Week .

[dealit] 02/7/2022 11:02

Hopefully you are correct "20" and good news.

[swerves1] 01/7/2022 16:27

Monday RNS!

[snowy20] 01/7/2022 16:14

Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.

[snowy20] 01/7/2022 16:03

GDR let it out time to get back to Quid .

[snowy20] 01/7/2022 15:16

RNS 30 MAY 2022


Point-of-Care Genedrive® COV19-ID Kit receives Coronavirus Test Device Approval ("CTDA")



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive® COV19-ID Kit in the United Kingdom. Genedrive's application for approval, under the requirements that came into force on 28 July 2021 via The Medical Devices (Coronavirus Test Device Approvals Regulations (2021)), was made on 21 December 2021.



Since submission for approval, the product has undergone positive external validation, commercial partners have been engaged in specific countries, and product claims have been expanded to include the testing of asymptomatic patients.



Information about the Genedrive® COV19-ID Kit can be found at hxxps://www.genedrive.com/assays/cov19-id-assay.php



David Budd, CEO of genedrive plc, said: "We are very pleased to have received a CTDA, which now allows the UK access to the fastest point-of-care COVID molecular test. The performance of the test has met CTDA standards in all regards, which positions genedrive well to engage in opportunities as they develop going forwards in the UK."



The Genedrive® COV19-ID Kit is a rapid molecular diagnostic test that delivers positive results as quickly as 7.5 minutes and negative results at 17 minutes. It utilises Reverse-Transcription Loop Mediated Isothermal Amplification (RT-LAMP) and a proprietary buffer formulation to achieve rapid results without requirement for user viral extraction steps. Performed directly from a mid-turbinate nasal swab, the assay targets the ORF1ab and N genes of the SARS-CoV-2 genome, adding robustness against emerging SARS-CoV-2 variants.